Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channels
- PMID: 24070813
- DOI: 10.1016/j.ejphar.2013.09.029
Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channels
Abstract
Class IC antiarrhythmic drugs are commonly used for rhythm control in atrial fibrillation. In addition, class I drugs are administered to suppress ventricular tachyarrhythmia in selected cases. The multichannel blocking profile of class I compounds includes reduction of cardiac potassium currents in addition to their primary mechanism of action, sodium channel inhibition. Blockade of two-pore-domain potassium (K2P) channels in the heart causes action potential prolongation and may provide antiarrhythmic action in atrial fibrillation. This study was designed to elucidate inhibitory effects of class I antiarrhythmic drugs on K2P channels. Human K2P2.1 (TREK1) and hK2P3.1 (TASK1) channels were systematically tested for their sensitivity to clinically relevant class IA (ajmaline), class IB (mexiletine), and class IC (propafenone) antiarrhythmic compounds using whole-cell patch clamp and two-electrode voltage clamp electrophysiology in Chinese hamster ovary cells and in Xenopus oocytes. Mexiletine and propafenone inhibited hK2P2.1 (IC50,mexiletine=173µM; IC50,propafenone=7.6µM) and hK2P3.1 channels (IC50,mexiletine=97.3µM; IC50,propafenone=5.1µM) in mammalian cells. Ajmaline did not significantly reduce current amplitudes. K2P channels were blocked in open and closed states, resulting in resting membrane potential depolarization. Open rectification properties of the channels were not affected by class I drugs. In summary, class I antiarrhythmic drugs target cardiac K2P K(+) channels. Blockade of hK2P2.1 and hK2P3.1 potassium currents provides mechanistic evidence to establish cardiac K2P channels as antiarrhythmic drug targets.
Keywords: Ajmaline; Antiarrhythmic drug; Cardiac arrhythmia; Cellular excitability; K(2P) channel; Membrane potential; Mexiletine; Propafenone.
© 2013 Elsevier B.V. All rights reserved.
Similar articles
-
Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant--comparison with flecainide.Eur J Pharmacol. 2014 Feb 5;724:51-7. doi: 10.1016/j.ejphar.2013.12.030. Epub 2013 Dec 27. Eur J Pharmacol. 2014. PMID: 24374008
-
Vernakalant activates human cardiac K(2P)17.1 background K(+) channels.Biochem Biophys Res Commun. 2014 Aug 29;451(3):415-20. doi: 10.1016/j.bbrc.2014.07.133. Epub 2014 Aug 7. Biochem Biophys Res Commun. 2014. PMID: 25108155
-
Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels.Naunyn Schmiedebergs Arch Pharmacol. 2012 Oct;385(10):1003-16. doi: 10.1007/s00210-012-0780-9. Epub 2012 Jul 13. Naunyn Schmiedebergs Arch Pharmacol. 2012. PMID: 22790794
-
Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept.Eur J Pharmacol. 2014 Sep 5;738:250-5. doi: 10.1016/j.ejphar.2014.05.056. Epub 2014 Jun 10. Eur J Pharmacol. 2014. PMID: 24927994 Review.
-
[Cardiac two-pore-domain potassium channels (K2P): Physiology, pharmacology, and therapeutic potential].Dtsch Med Wochenschr. 2012 Aug;137(33):1654-8. doi: 10.1055/s-0032-1305216. Epub 2012 Aug 8. Dtsch Med Wochenschr. 2012. PMID: 22875694 Review. German.
Cited by
-
The Experimental TASK-1 Potassium Channel Inhibitor A293 Can Be Employed for Rhythm Control of Persistent Atrial Fibrillation in a Translational Large Animal Model.Front Physiol. 2021 Jan 21;11:629421. doi: 10.3389/fphys.2020.629421. eCollection 2020. Front Physiol. 2021. PMID: 33551849 Free PMC article.
-
TREK-1 in the heart: Potential physiological and pathophysiological roles.Front Physiol. 2022 Dec 22;13:1095102. doi: 10.3389/fphys.2022.1095102. eCollection 2022. Front Physiol. 2022. PMID: 36620226 Free PMC article. Review.
-
Antiarrhythmic Properties of Ranolazine: Inhibition of Atrial Fibrillation Associated TASK-1 Potassium Channels.Front Pharmacol. 2019 Nov 26;10:1367. doi: 10.3389/fphar.2019.01367. eCollection 2019. Front Pharmacol. 2019. PMID: 32038227 Free PMC article.
-
Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.J Am Heart Assoc. 2020 May 18;9(10):e015751. doi: 10.1161/JAHA.119.015751. Epub 2020 May 9. J Am Heart Assoc. 2020. PMID: 32390491 Free PMC article.
-
Voltage-gated and stretch-activated potassium channels in the human heart : Pathophysiological and clinical significance.Herzschrittmacherther Elektrophysiol. 2018 Mar;29(1):36-42. doi: 10.1007/s00399-017-0541-z. Epub 2018 Jan 5. Herzschrittmacherther Elektrophysiol. 2018. PMID: 29305705 Review. English.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources